



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61P 7/02, 9/12, A61K 31/715, 45/06, 38/49, 38/02, 31/42, 31/60 // (A61K 38/49, 31:415) (A61K 38/02, 31:415) (A61K 45/06, 31:715, 31:415) (A61K 31/60, 31:415) (A61K 31/42, 31:415)		A1	(11) International Publication Number: WO 00/53264 (43) International Publication Date: 14 September 2000 (14.09.00)
(21) International Application Number: PCT/US00/06451 (22) International Filing Date: 10 March 2000 (10.03.00)		(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/123,815 11 March 1999 (11.03.99) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19807 (US).			
(72) Inventor: WONG, Pancras, C.; 3227 Whiteman Road, Wilmington, DE 19808 (US).			
(74) Agent: RUBIN, Kenneth, B.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).			
(54) Title: TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIb/IIIa ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN			
(57) Abstract			
<p>Provided is a method of treating thrombosis in mammals by administering therapeutically effective amounts of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose. Preferably, the combination of (i) and (ii) provides a synergistic effect.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

Title

Treatment of Thrombosis by Combined Use of a Factor Xa Inhibitor and Aspirin, Tissue Plasminogen Activator (TPA),
5 a GPIIb/IIIa Antagonist, Low Molecular Weight Heparin or Heparin.

Field of the Invention

10 This invention relates to the treatment of thrombosis in mammals and more particularly to such treatment by the administration of a combination of (i) a Factor Xa inhibitor, and (II) a compound selected from the group consisting of aspirin, TPA, GPIIb/IIIa antagonist, low
15 molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose.

Background of the Invention

20 The selected class of Factor Xa inhibitors and the selected class of aspirin, GPIIb/IIIa antagonist, tissue plasminogen activator (TPA), low-molecular-weight-heparin and heparin are essential as component parts of the novel
25 compositions of this invention. Aspirin and GPIIb/IIIa antagonists are known in the art as antiplatelet agents. Tissue plasminogen activator (TPA) is known as a thrombolytic agent. Low-molecular-weight heparin and heparin are known as anticoagulants.

30 Factor Xa is a blood coagulation protein. It plays a major role in blood coagulation because of its central position at the convergent point of the

intrinsic and extrinsic pathways of coagulation. It is believed that inhibition of Factor Xa may eliminate the production of thrombin by either the extrinsic or intrinsic pathways without interfering with a basal level of thrombin activity necessary for normal hemostasis (Harke LA, Hanson SR and Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. *Thrombosis and Haemostasis* 78: 736-741, 1997).

Both peptide and nonpeptide Factor Xa inhibitors are currently available (Kaiser B. Thrombin and factor Xa inhibitors. *Drugs of the Future* 23: 423-436, 1998). Examples of peptide Factor Xa inhibitors are antistasin and tick anticoagulant peptide, and nonpeptide Factor Xa inhibitors are described in WO98/2326, *Thromb Haemost* 1994; 71: 314-9, *Thromb Haemost* 1994; 72:393-6, and *Thromb Haemost* 1998; 79: 859-64. The antithrombotic effects of these peptide and nonpeptide Factor Xa inhibitors have been well demonstrated in various experimental models of arterial and venous thrombosis (Kaiser B. Thrombin and factor Xa inhibitors. *Drugs of the Future* 23: 423-436, 1998).

Summary of the Invention

One object of the present invention is to provide a method of treating thrombosis in a mammal comprising: administering to said mammal a therapeutically effective amount of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose.

Another object of the present invention is to provide a method of treating thrombosis in a mammal wherein the combination of (i) and (ii) above are administered in amounts to provide a synergistic effect.

5

These and other objects, which will become apparent during the following detailed description, have been achieved by the discovery that the administration of a Factor Xa inhibitor (i) in combination with one of (ii) 10 aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin, with at least one of (i) and (ii), preferably both, being administered at a dose which would be a subtherapeutic dose when administered alone.

15

Brief Description of Drawings

Fig. 1 is a graph showing carotid blood flow versus time for saline vehicle, aspirin alone, a Factor Xa inhibitor alone, and a combination of aspirin and the same 20 Factor Xa inhibitor;

Fig. 2 is a graph showing carotid blood flow versus time for saline vehicle, a GPIIb/IIIa antagonist alone, a 25 Factor Xa inhibitor alone, and a combination of the same IIb/IIIa antagonist and Factor X inhibitor;

Fig. 3 is a graph showing carotid blood flow versus time for saline vehicle, fragmin, a Factor Xa inhibitor, 30 and a combination of fragmin and the same Factor Xa inhibitor;

Fig. 4 is a bar chart showing the duration of

patency for saline vehicle, a Factor Xa inhibitor alone, TPA alone, and a combination of the same TPA and Factor Xa inhibitor; and

5 Fig. 5 is a bar chart showing the antithrombotic effect of a saline vehicle and heparin alone, and a combination of heparin with 3 different doses of a Factor Xa inhibitor.

10 Detailed Description of the Invention


The combinations of active compounds (i) and (ii) of this invention are useful in the treatment of thrombotic disorders including atherosclerotic arterial disease, 15 valvular heart disease, heart failure, cerebrovascular disease such as stroke, atrial fibrillation, coronary artery disease such as myocardial infarction and unstable angina, coronary artery bypass grafts, peripheral vascular disease, thromboembolic complications of prosthetic 20 cardiovascular devices such heart valves and vascular grafts and deep vein thrombosis following major orthopaedic surgery, major fractures and/or abdominal surgery. These combinations are also expected to be useful in combining with endovascular stenting procedures such as percutaneous 25 transluminal coronary angioplasty to prevent subsequent arterial thrombus formation and reocclusion.

Factor Xa inhibitor compounds (i) useful in the present invention are well-known in the prior art.

30 Preferred Factor Xa inhibitors are described in PCT Pat. Appn. No. US97/22895, filed December 15, 1997; published July 2, 1998, as WO98/28269, the disclosure of which is hereby incorporated by reference. Specifically preferred compounds within WO98/28269 are:

Compound (1) :

5




10


Compound (2) :

15 Compound (3) :

20



HCl Salt




25

Another Factor Xa inhibitor compound is DX-9065a

described in Thromb Haemost 1994; 71:314-9; and Thromb Haemost 1994; 72:393-6. DX-9065a is (+)-2S-2[4-[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-[7-amidino-2-naphthyl] propanoic acid hydrochloride pentahydrate. A still further Factor Xa inhibitor compound is YM-60828 described in Thromb Haemost 1998; 79:859-64. YM-60828 is [N-[4-[(1-acetimidoyl-4-piperidyl)oxy] phenyl]-N-[(7-amidino-2-naphthyl)methyl]sulfamoyl] acetic acid dihydrochloride. Other Factor Xa inhibitor compounds will be readily known by those skilled in the art.

The compounds (ii) useful in the combination of the present invention are either commercially available and/or well-known in the prior art. Aspirin, fragmin (Pharmacia AB, Stockholm, Sweden), heparin (Upjohn, Kalamazoo, Michigan), and TPA (Genentech, San Francisco, California) are available commercially. Fragmin is a low molecular weight heparin. It is isolated from standard heparin with a mean molecular weight of 4.5 kDa whereas standard heparin has a molecular weight of 750 to 1000 kDa. Low-molecular-weight heparin such as fragmin differs from heparin in both their pharmacokinetic properties and mechanism of action. The potency for fragmin is expressed in unit of anti-Factor Xa activity. Each mg of fragmin has about 150 U of anti-Factor Xa activity.

Preferred GPIIb/IIIa antagonist compounds useful as component (ii) of the combination are described in published PCT Application WO95/14683, published 1 June 1995, as the second embodiment. Preferred compounds described therein have the formula:




(Ia)

5

or a pharmaceutically acceptable salt thereof,
wherein:

10 R1 is selected from R2a(R3)N-, R2(R3)N(R2N=)C-,
R2a(R3)N(CH2)p'Z-, R2(R3)N(R2N=)C(CH2)p"Z-,
R2(R3)N(R2N=)CN(R2)-, R2(R3)NC(O)-, R2(R5O)N(R2N=)C-,
R2(R3)N(R5ON=)C-;



15

Z is selected from a bond, O, or S;

R2 and R3 are independently selected from: H; C1-C6 alkyl;
20 C7-C11 arylalkyl optionally substituted with 0-3 groups
selected from hydroxy, halogen, C1-C6 alkoxy, C1-C6 alkyl,
CF3, S(O)mCH3, -N(CH3)2, C1-C4 haloalkyl,
methylenedioxydiyl, ethylenedioxydiyl; (C1-C10
alkoxy)carbonyl; aryl(C1-C10 alkoxy)carbonyl where the aryl
25 group is optionally substituted with 0-3 groups selected
from hydroxy, halogen, C1-C6 alkoxy, C1-C6 alkyl, CF3,

S(O)mCH₃, -N(CH₃)₂, C₁-C₄ haloalkyl, methylenedioxydiyl, ethylenedioxydiyl; or heteroaryl(C₁-C₅)alkyl where the heteroaryl group is optionally substituted with 0-2 groups selected from hydroxy, halogen, C₁-C₆ alkoxy, C₁-C₆ alkyl,
5 CF₃, S(O)mCH₃, -N(CH₃)₂, C₁-C₄ haloalkyl, methylenedioxydiyl, ethylenedioxydiyl;

R_{2a} is R₂ or R₂(R₃)N(R₂N=C)C;

10 U is a single bond,

V is selected from:

a single bond;

15 -(C₁-C₇ alkyl)-, substituted with 0-3 groups independently selected from R⁶ or R⁷;
-(C₂-C₇ alkenyl)-, substituted with 0-3 groups independently selected from R⁶ or R⁷;
-(C₂-C₇ alkynyl)-, substituted with 0-3 groups
20 independently selected from R⁶ or R⁷;
-(phenyl)-Q-, said phenyl substituted with 0-2 groups independently selected from R⁶ or R⁷;
-(pyridyl)-Q-, said pyridyl substituted with 0-2 groups independently selected from R⁶ or R⁷; or
25 -(pyridazinyl)-Q-, said pyridazinyl substituted with 0-2 groups independently selected from R⁶ or R⁷,

Q is selected from

a single bond,

30 -O-, -S(O)_m-, -N(R¹²)-, -(CH₂)_m-, -C(=O)-, -
N(R^{5a})C(=O)-, -C(=O)N(R^{5a})-, -CH₂O-, -OCH₂-, -

$\text{CH}_2\text{N}(\text{R}^{12})-$, $-\text{N}(\text{R}^{12})\text{CH}_2-$, $-\text{CH}_2\text{C}(=\text{O})-$, $-\text{C}(=\text{O})\text{CH}_2-$, $-\text{CH}_2\text{S(O)}_m-$, or $-\text{S(O)}_m\text{CH}_2-$,

5 provided that when b is a single bond, and $\text{R}^1\text{-U-V-}$ is a substituent on C5 of the central 5-membered ring of Formula Ic, then Q is not $-\text{O}-$, $-\text{S(O)}_m-$, $-\text{N}(\text{R}^{12})-$, $-\text{C}(=\text{O})\text{N}(\text{R}^{5a})-$, $-\text{CH}_2\text{O}-$, $\text{CH}_2\text{N}(\text{R}^{12})-$ or $-\text{CH}_2\text{S(O)}_m-$;

W is selected from:

10 $-(\text{C}(\text{R}^4)_2)-\text{C}(=\text{O})-\text{N}(\text{R}^{5a})-$, or
 $-\text{C}(=\text{O})-\text{N}(\text{R}^{5a})-(\text{C}(\text{R}^4)_2)-$;

X is $-\text{C}(\text{R}^4)(\text{R}^8)-\text{CHR}^{4a}-$;

15 R^4 is selected from H, C₁-C₁₀ alkyl, C₁-C₁₀ alkylcarbonyl, aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;

20 R^{4a} is selected from hydroxy, C₁-C₁₀ alkoxy, nitro, -N(R⁵)R^{5a}, -N(R¹²)R¹³, or -N(R¹⁶)R¹⁷, aryl substituted with 0-3 R⁶, or (C₁-C₁₀ alkyl)carbonyl;

25 R^{4b} is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, nitro, (C₁-C₆ alkyl)carbonyl, C₆-C₁₀ aryl, -N(R¹²)R¹³, halo, CF₃, CN, (C₁-C₆ alkoxy)carbonyl, carboxy, piperidinyl, morpholinyl or pyridyl;

R⁵ is selected from H or C₁-C₁₀ alkyl substituted with 0-6

R^{4b};

5 R^{5a} is selected from hydrogen, hydroxy, C₁ to C₈ alkyl,
C₂ to C₆ alkenyl, C₃ to C₁₁ cycloalkyl, C₄ to C₁₁
cycloalkylmethyl, C₁-C₆ alkoxy, benzyloxy, C₆ to C₁₀
aryl, heteroaryl, heteroarylalkyl, C₇ to C₁₁
arylalkyl, or adamantylmethyl, C₁-C₁₀ alkyl
10 substituted with 0-2 R^{4b};

15 alternately, R⁵ and R^{5a} can be taken together to be 3-
azabicyclononyl, 1,2,3,4-tetrahydro-1-quinolinyl,
1,2,3,4-tetrahydro-2-isouinolinyl, 1-piperidinyl, 1-
morpholinyl, 1-pyrrolidinyl, thiamorpholinyl,
thiazolidinyl or 1-piperazinyl, each being optionally
substituted with C₁-C₆ alkyl, C₆-C₁₀ aryl, heteroaryl,
C₇-C₁₁ arylalkyl, (C₁-C₆ alkyl)carbonyl, (C₃-C₇
20 cycloalkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl or (C₇-C₁₁
arylalkoxy)carbonyl;

25 R^{5b} is selected from C₁-C₈ alkyl, C₂-C₆ alkenyl, C₃-C₁₁
cycloalkyl, C₄-C₁₁ cycloalkylmethyl, C₆-C₁₀ aryl, C₇-
C₁₁ arylalkyl, or C₁-C₁₀ alkyl substituted with 0-2
R^{4b}

Y is selected from hydroxy, C₁ to C₁₀ alkyloxy, C₃ to
C₁₁ cycloalkyloxy, C₆ to C₁₀ aryloxy, C₇ to C₁₁
aralkyloxy, C₃ to C₁₀ alkylcarbonyloxyalkyloxy, C₃ to
30 C₁₀ alkoxy carbonyloxyalkyloxy, C₂ to C₁₀

alkoxycarbonylalkyloxy, C₅ to C₁₀
cycloalkylcarbonyloxyalkyloxy, C₅ to C₁₀
cycloalkoxycarbonyloxyalkyloxy, C₅ to C₁₀
cycloalkoxycarbonylalkyloxy, C₇ to C₁₁
5 aryloxycarbonylalkyloxy, C₈ to C₁₂
 aryloxycarbonyloxyalkyloxy, C₈ to C₁₂
 arylcarbonyloxyalkyloxy, C₅ to C₁₀
 alkoxyalkylcarbonyloxyalkyloxy, C₅ to C₁₀ (5-alkyl-
 1,3-dioxa-cyclopenten-2-one-yl)methyloxy, or C₁₀ to
10 C₁₄ (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyloxy;

R⁶ and R⁷ are each independently selected from H, C₁-C₁₀

alkyl, hydroxy, C₁-C₁₀ alkoxy, nitro, (C₁-C₁₀
alkyl)carbonyl, -N(R¹²)R¹³, cyano, or halo;

15

R¹² and R¹³ are each independently selected from H, C₁-C₁₀

alkyl, (C₁-C₁₀ alkoxy)carbonyl, (C₁-C₁₀

alkyl)carbonyl, C₁-C₁₀ alkylsulfonyl,

aryl(C₁-C₁₀ alkyl)sulfonyl, arylsulfonyl,

20

heteroarylsulfonyl, heteroarylcarbonyl,

heteroarylalkylcarbonyl or aryl, wherein said aryl

groups being optionally substituted with 0-3

substituents selected from the group consisting of:

C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and NO₂;

25

R¹⁵ is selected from H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl,

C₂-C₁₀ alkynyl, C₁-C₁₀ alkoxy, aryl, heteroaryl or

(C₁-C₁₀ alkoxy)carbonyl, CO₂R⁵ or -C(=O)N(R⁵)R^{5a};

30 R¹⁶ is selected from:

-C(=O)-O-R^{18a},
-C(=O)-R^{18b},
-C(=O)N(R^{18b})₂,
-SO₂-R^{18a}, or
5 -SO₂-N(R^{18b})₂;

R¹⁷ is selected from: H or C₁-C₅ alkyl ;

R^{18a} is selected from:

10 C₁-C₈ alkyl substituted with 0-2 R¹⁹,
C₂-C₈ alkanyl substituted with 0-2 R¹⁹,
C₂-C₈ alkynyl substituted with 0-2 R¹⁹,
C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹,
aryl substituted with 0-4 R¹⁹,
15 aryl(C₁-C₆ alkyl)- substituted with 0-4 R¹⁹,

a heterocyclic ring system selected from pyridinyl,
furanyl, thiazolyl, thieryl, pyrrolyl, pyrazolyl,
triazolyl, imidazolyl, benzofuranyl, indolyl,
20 indolinyl, quinolinyl, isoquinolinyl, isoxazolyl,
isoxazolinyl, benzimidazolyl, piperidinyl,
tetrahydrofuranyl, pyranyl, pyrimidinyl, 3H-indolyl,
pyrrolidinyl, piperidinyl, indolinyl, or morpholinyl,
said heterocyclic ring being substituted with 0-4 R¹⁹;

25 C₁-C₆ alkyl substituted with a heterocyclic ring
system selected from pyridinyl, furanyl, thiazolyl,
thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl,
isoxazolinyl, benzofuranyl, indolyl, indolenyl,
30 quinolinyl, isoquinolinyl, benzimidazolyl,

piperidinyl, tetrahydrofuranyl, pyranyl, pyridinyl,
 3H-indolyl, indolyl, pyrrolidinyl, piperidinyl,
 indolinyl, or morpholinyl, said heterocyclic ring
 being substituted with 0'-4 R¹⁹;

5


R^{18b} is selected from R^{18a} or H;

R¹⁹ is selected from H, halogen, CF₃, CN, NO₂, NR¹²R¹³, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, 10 C₃-C₁₁ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl, aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkyl)sulfonyl, aryl-sulfonyl, or C₁-C₄ alkoxy carbonyl;

n is 0-4;
 15 p' is 1-7;
 p'' is 1-7;
 r is 0-3.


More preferred compounds have the formula:

20



or a pharmaceutically acceptable salt thereof,
 25 wherein:

R¹ is selected from: R^{2a}(R³)N-, R²NH(R²N=)C-, R²NH(R²N=)CNH-, R^{2a}(R³)N(CH₂)_{p'}Z-, R²NH(R²N=)C(CH₂)_{p''}Z-, R²(R³)NC(O)-, R²(R⁵O)N(R²N=)C-, 30 R²(R³)N(R⁵ON=)C-;



5 n is 0-1;

p' is 4-6;

p" is 2-4;

10

Z is selected from a bond or O;

V is a single bond, -(phenyl)- or -(pyridyl)-;

15 W is selected from:

-(C(R⁴)₂)-C(=O)-N(R^{5a})-,
-C(=O)-N(R^{5a})-CH₂-;

X is selected from:

20 -CH₂-CH(N(R¹⁶)R¹⁷)-, or
-CH₂-CH(NR⁵R^{5a})-;

Y is selected from:

hydroxy;

25 C₁ to C₁₀ alkoxy;

methylcarbonyloxymethoxy-;

ethylcarbonyloxymethoxy-;
t-butylcarbonyloxymethoxy-;
cyclohexylcarbonyloxymethoxy-;
1-(methylcarbonyloxy)ethoxy-;
5 1-(ethylcarbonyloxy)ethoxy-;
1-(t-butylcarbonyloxy)ethoxy-;
1-(cyclohexylcarbonyloxy)ethoxy-;
i-propyloxycarbonyloxymethoxy-;
t-butyloxycarbonyloxymethoxy-;
10 1-(i-propyloxycarbonyloxy)ethoxy-;
1-(cyclohexyloxycarbonyloxy)ethoxy-;
1-(t-butyloxycarbonyloxy)ethoxy-;
dimethylaminoethoxy-;
diethylaminoethoxy-;
15 (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-;
(5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-;
(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-;
1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;

20 R¹⁶ is selected from:

-C(=O)-O-R^{18a},
-C(=O)-R^{18b},
-S(=O)₂-R^{18a} or
-SO₂-N(R^{18b})₂;

25

R¹⁷ is selected from H or C₁-C₅ alkyl;

R^{18a} is selected from:

C₁-C₈ alkyl substituted with 0-2 R¹⁹,
30 C₂-C₈ alkenyl substituted with 0-2 R¹⁹,
C₂-C₈ alkynyl substituted with 0-2 R¹⁹,


C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹,
 aryl substituted with 0-4 R¹⁹,
 aryl(C₁-C₆ alkyl)- substituted with 0-4 R¹⁹,

5 a heterocyclic ring system selected from pyridinyl,
 furanyl, thiazolyl, thienyl, pyrrolyl, pyrazolyl,
 triazolyl, imidazolyl, benzofuranyl, indolyl,
 indolinyl, quinolinyl, isoquinolinyl, isoxazolyl,
 isoxazolinyl, benzimidazolyl, piperidinyl,
 10 tetrahydrofuranyl, pyranyl, pyrimidinyl, 3H-indolyl,
 pyrrolidinyl, piperidinyl, indolinyl, or morpholinyl,
 said heterocyclic ring being substituted with 0-4 R¹⁹;

15 C₁-C₆ alkyl substituted with a heterocyclic ring
 system selected from pyridinyl, furanyl, thiazolyl,
 thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl,
 isoxazolinyl, benzofuranyl, indolyl, indolenyl,
 quinolinyl, isoquinolinyl, benzimidazolyl,
 piperidinyl, tetrahydrofuranyl, pyranyl, pyridinyl,
 20 3H-indolyl, indolyl, pyrrolidinyl, piperidinyl,
 indolinyl, or morpholinyl, said heterocyclic ring
 being substituted with 0-4 R¹⁹.

25 A specifically preferred compound has the
 formula:

Compound (4):



Other salts of this compound are also specifically preferred.

10 Specific examples of other GPIIb/IIIa antagonist compounds are abciximab, eptifibatide, tirofiban, lamifiban, lefradafiban, sibrafiban (Ro-48-3657), orbofiban and xemilofiban described in the paper of Graul et al. and Scarborough (Graul A, Martel AM and Castaner J.

15 Xemilifiban; Drugs of the Future 22: 508-517, 1997; Scarborough RM; Eptifibatide. Drugs of the Future 23: 585-590, 1998). Others will be readily apparent to those skilled in the art.

20 "Therapeutically effective amount" is intended to include an amount of a combination of compounds claimed effective to treat thrombosis in a mammal. The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv.

25 Enzyme Regul. 22:27-55 (1984), occurs when the effect (in this case, an antithrombotic effect) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly

30 demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of antihypertensive effect, antithrombotic effect, or some other non-additive beneficial effect of the combination compared with the

individual components.

By "administered in combination", "combination", or "combined" when referring to component (i) and component (ii) of the present invention, it is meant that the components are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order or at different points in time. Thus, component (i) and component (ii) may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.

By "subtherapeutic dose" when referring to component (i) and component (ii) of the present invention, it is meant that each component when administered to a mammal alone does not give the desired therapeutic effect for the disease being treated.

The invention can be understood further by the following examples wherein Compounds (1) - (4) are as shown above. Saline (0.9 weight % NaCl) is the vehicle in all examples.

25

Example 1

The combination of aspirin and a Factor Xa inhibitor

Rabbits were anesthetized with ketamine (50 mg/kg i.m.) and xylazine (10 mg/kg i.m.) and then surgically prepared with arterial and venous catheters. An electromagnetic flow probe was placed on a segment of an isolated carotid artery to monitor blood flow. Thrombus

formation was induced by electrical stimulation of the carotid artery for 3 min at 4 mA using an external stainless-steel bipolar electrode. Carotid blood flow was measured continuously over a 90-min period to monitor
5 thrombus occlusion. Test agents were infused intravenously 1 hour prior to the electrical stimulation of the carotid artery and continuously during the 90-min period.

As shown in Fig. 1 following the electrical
10 stimulation, thrombus formation was induced and carotid blood flow was gradually declined in saline vehicle-treated animals. At about 40 min after stimulation, the artery was totally occluded and blood flow was zero. Aspirin at 1 mg/kg/hr i.v. (concentration in saline was 0.167 mg/ml) or
15 Compound (1) (a Factor Xa inhibitor) at 0.1 mg/kg/hr i.v. (concentration in saline was 0.017 mg/ml) did not prevent the occlusion of the artery; and blood flow in these animals was decreased to zero at about the same time as those in vehicle-treated animals. Surprisingly, Compound
20 (1) 0.1 mg/kg/hr i.v. in combination with aspirin at 1 mg/kg/hr i.v. prevented the artery from occlusion and maintained the blood flow for at least 90 min. These results indicate that a combination of Compound (1) and aspirin at their subtherapeutic doses unexpectedly produced
25 a significant antithrombotic effect in a rabbit model of arterial thrombosis.

Example 2

30 The combination of Compound (4) (a GP-IIb/IIIa antagonist) and a Factor Xa inhibitor

Experimental protocol was described as above for

Example 1. As shown in Figure 2, Compound (4) (a GP-IIb/IIIa antagonist) at 0.03 mg/kg/hr i.v. and Compound (3) (a Factor Xa inhibitor) at 0.1 mg/kg/hr i.v. did not prevent the occlusion of the artery; and blood flow in 5 these animals was decreased to zero at about the same time as those in vehicle-treated animals. Surprisingly, Compound (3) at 0.1 mg/kg/hr i.v. (concentration in saline was 0.017 mg/ml) in combination with Compound (4) at 0.03 mg/kg/hr i.v. (concentration in saline was 0.005 mg/ml) 10 prevented the artery from occlusion and maintained the blood flow for at least 90 min. These results indicate that a combination of Compound (3) and Compound (4) at their subtherapeutic doses unexpectedly produced a significant antithrombotic effect in a rabbit model of 15 arterial thrombosis.

Example 3

The combination of fragmin (low-molecular-weight-heparin) 20 and a Factor Xa inhibitor

Experimental protocol was described as above for Example 1. As shown in Figure 3, fragmin (a low-molecular-weight-heparin) at 60 U/kg/hr i.v. was moderately active. 25 Compound (3) (a Factor Xa inhibitor) at 0.1 mg/kg/hr i.v. did not prevent the occlusion of the artery; and blood flow in these animals was decreased to zero similar to those in vehicle-treated animals. Surprisingly, Compound (3) at 0.1 mg/kg/hr i.v. (concentration in saline was 0.017 mg/ml) in 30 combination with fragmin at 60 U/kg/hr i.v. (concentration in saline was 0.067 mg/ml or 10 U/ml) prevented the artery from occlusion and maintained the blood flow for at least 90 min. These results indicate that a combination of

Compound (3) at its subtherapeutic dose and fragmin at a medium dose unexpectedly produced a significant antithrombotic effect in a rabbit model of arterial thrombosis.

5

Example 4

The combination of recombinant tissue-type plasminogen activator (TPA) and a Factor Xa inhibitor

10

Experiments were conducted in rats. It is similar to that of the rabbit protocol as described above in Example 1 except that Compound (2) and/or TPA were given 5 min after a preformed clot was formed. The measured parameter is 15 its duration of patency. As shown in Figure 4, five minutes after the induction of occlusive thrombosis, neither Compound (2) at 5.6 mg/kg (concentration in saline was 0.23 mg/ml) and 1.4 mg/kg/hr i.v. nor TPA at 1 mg/kg i.v. (concentration in saline was 1 mg/ml) produced a 20 therapeutic effect on the duration of patency. However, a combination of Compound (2) at 5.6 mg/kg and 1.4 mg/kg/hr i.v., and TPA at 1 mg/kg i.v. increased the duration of patency to 70%. This result suggests that a Factor Xa inhibitor such as Compound (2) is a promising useful 25 adjunctive agent, which accelerates thrombolysis induced by TPA or other thrombolytic agents. Compound (2) enhanced the thrombolysis induced by a subtherapeutic dose of TPA.

Example 5

30

The combination of heparin and a Factor Xa inhibitor

Experiments were conducted in male guinea pigs

anesthetized with a mixture of ketamine (90 mg/kg i.m.) and xylazine (12 mg/kg i.m.). The arterio-venous shunt was connected between the carotid artery and jugular vein. The exposure of flowing blood to a silk thread induced the formation of a significant thrombus. Thirty minutes later, the shunt was disconnected and the silk thread covered with thrombus was weighed. The compounds or saline vehicle were given as continuous i.v. infusion starting 1 hr before blood was circulated in the shunt and continuing throughout the experiment (i.e., 90 min). As shown in figure 5, heparin at 4 U/kg/hr i.v. (concentration in saline was 0.667 U/ml) did not cause antithrombotic effect. However, heparin at 4 U/kg/hr i.v. potentiated the antithrombotic effects of Compound (3) (a Factor Xa inhibitor) at 0.3, 1 or 3 mg/kg/hr i.v. (concentration in saline for 0.3 dose was 0.05 mg/ml). This result suggests that heparin at a subtherapeutic dose enhances the antithrombotic effect of Compound (3) in a guinea model of venous thrombosis.

The results presented indicate that a combination therapy comprising a Factor Xa inhibitor and one of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin or heparin will be effective in treating thrombosis in patients. The method of the present invention provides important advantages over currently available treatments for thrombosis.

DOSAGE AND FORMULATION

The Factor Xa inhibitor (i) and a compound (ii) of this invention can be administered as treatment for thrombosis by any means that produces contact of the active agent with the agents site of action, i.e., Factor Xa, in

the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be
5 administered alone, but preferably are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

10 The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind
15 of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.01 to about 30 mg/kg.

20 Dosage forms of compositions suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be
25 present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be
30 administered parenterally, in sterile liquid dosage forms.

 Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose

derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous 5 release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for 10 oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols 15 such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing 20 agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts, and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, 25 methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, a standard reference text in this field, the disclosure of which is hereby incorporated by 30 reference.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as

follows:

Capsules

A large number of unit capsules can be prepared by
5 filling standard two-piece hard gelatin capsules each with
0.1 to 100 mg of powdered active ingredient, 150 mg of
lactose, 50 mg of cellulose, and 6 mg magnesium stearic.

Soft Gelatin Capsules

10 A mixture of active ingredient in a digestible oil
such as soybean oil, cottonseed oil or olive oil can be
prepared and injected by means of a positive displacement
pump into gelatin to form soft gelatin capsules containing
0.1 to 100 mg of the active ingredient. The capsules
15 should then be washed and dried.

Tablets

A large number of tablets can be prepared by
conventional procedures so that the dosage unit is 0.1 to
20 100 mg of active ingredient, 0.2 mg of colloidal silicon
dioxide, 5 milligrams of magnesium stearate, 275 mg of
microcrystalline cellulose, 11 mg of starch and 98.8 mg of
lactose. Appropriate coatings may be applied to increase
palatability or delay absorption.

25

Suspension

An aqueous suspension can be prepared for oral
administration so that each 5 mL contain 0.1 to 100 mg of
finely divided active ingredient, 200 mg of sodium
30 carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of
sorbitol solution, U.S.P., and 0.025 mg of vanillin.

Injectable

A parenteral composition suitable for administration by injection can be prepared by stirring 0.1 to 100 mg by weight of active ingredient in 10% by volume propylene glycol and water. The solution is sterilized by commonly used techniques.

5 Combination of components (i) and (ii)

Each therapeutic agent component of this invention can independently be in any dosage form, such as those described above, and can also be administered in various ways, as described above. In the following description component (ii) is to be understood to represent one or more agents as described previously. Thus, if components (i) and (ii) are to be treated the same or independently, each agent of component (ii) may also be treated the same or independently.

Components (i) and (ii) of the present invention may be formulated together, in a single dosage unit (that is, combined together in one capsule, tablet, powder, or liquid, etc.) as a combination product. When component (i) and (ii) are not formulated together in a single dosage unit, the component (i) may be administered at the same time as component (ii) or in any order; for example component (i) of this invention may be administered first, followed by administration of component (ii), or they may be administered in the reverse order. If component (ii) contains more than one agent, e.g., aspirin and heparin, these agents may be administered together or in any order. When not administered at the same time, preferably the administration of component (i) and (ii) occurs less than about one hour apart. Preferably, the route of administration of component (i) and (ii) is intravenously (i.v.). The terms oral agent, oral inhibitor, oral

compound, or the like, as used herein, denote compounds which may be orally administered. Although it is preferable that component (i) and component (ii) both be administered by the same route (that is, for example, both orally) or dosage form, if desired, they may each be administered by different routes (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) or dosage forms.

10 As is appreciated by a medical practitioner skilled in the art, the dosage of the combination therapy of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health 15 and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above.

The proper dosage of components (i) and (ii) of the present invention will be readily ascertainable by a 20 medical practitioner skilled in the art, based upon the present disclosure. By way of general guidance, typically a daily dosage may be about 0.01 milligram to about 1 gram of each component. If component (ii) represents more than one compound, then typically a daily dosage may be about 25 0.01 milligram to about 0.1 gram of each agent of component (ii). By way of general guidance, when the compounds of component (i) and component (ii) are administered in combination, the dosage amount of each component may be reduced by about 70-80% relative to the usual dosage of the 30 component when it is administered alone as a single agent for the treatment of thrombosis, in view of the synergistic effect of the combination.

The combination products of this invention may be

formulated such that, although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized. In order to minimize contact, for example, where the product is orally administered, one active ingredient may be enteric coated.

5 By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the

10 gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated

15 with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such

20 that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a

25 polymer such as a low viscosity grade of hydroxypropyl methylcellulose or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

30 In each formulation wherein contact is prevented between components (i) and (ii) via a coating or some other material, contact may also be prevented between the individual agents of component (ii).

Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are 5 blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more placebo layers may be 10 present such that the placebo layer is between the layers of active ingredients. In addition, dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or 15 non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non-perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient.

These as well as other ways of minimizing contact 20 between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time or concurrently by the same manner, will be readily apparent to those skilled in the art, based on the present 25 disclosure.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be 30 practiced otherwise than as specifically described herein.

What is claimed is:

1. A method of treating thrombosis in a mammal comprising: administering to said mammal a therapeutically effective amount of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose.
- 10
2. A method of Claim 1 wherein the combination of (i) and (ii) provides a synergistic effect.
- 15
3. A method of Claim 2 wherein (ii) is aspirin.
4. A method of Claim 2 wherein (ii) is TPA.
- 20
5. A method of Claim 2 wherein (ii) is a GPIIb/IIIa antagonist.
6. A method of Claim 2 wherein (ii) is a low molecular weight heparin.
- 25
7. A method of Claim 2 wherein (ii) is heparin.
8. The use of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin for the manufacture of a medicament for the treatment of thrombosis.
- 30

INTERNATIONAL SEARCH REPORT

Inte	rnational Application No
PCT/US 00/06451	

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7 A61P7/02 A61P9/12 A61K31/715 A61K45/06 A61K38/49 A61K38/02 A61K31/42 A61K31/60 // (A61K38/49, 31:415), (A61K38/02, 31:415), (A61K45/06, 31:715, 31:415), (A61K31/60, 31:415),				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols)				
IPC 7 A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
EPO-Internal				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.
P, X	DE 198 16 983 A (BOEHRINGER INGELHEIM PHARMA) 21 October 1999 (1999-10-21) page 12, line 1-7; claim 9 page 12, line 51-59 ---			1,2,4,8
P, X	WO 99 38827 A (MERCK & CO INC) 5 August 1999 (1999-08-05) page 3, line 30 -page 4, line 9 page 6, line 8-28; claims 1-3 page 6, line 1-7 page 7, line 26-35 ---			1,2,5,6, 8 3,4,7
P, X	WO 99 45913 A (MERCK & CO INC) 16 September 1999 (1999-09-16) page 7, line 5-12 page 22, line 30-32 page 34, line 9-13 ---			1,3-5,8
A				4,7
				-/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :				
"A" document defining the general state of the art which is not considered to be of particular relevance		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E" earlier document but published on or after the international filing date		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"O" document referring to an oral disclosure, use, exhibition or other means		"&" document member of the same patent family		
"P" document published prior to the international filing date but later than the priority date claimed				
Date of the actual completion of the international search		Date of mailing of the international search report		
3 August 2000		18/08/2000		
Name and mailing address of the ISA		Authorized officer		
European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Kanbier, D		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/06451

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 (A61K31/42, 31:415)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 28269 A (DU PONT MERCK PHARMA) 2 July 1998 (1998-07-02) cited in the application page 386, line 31 -page 389, line 10 page 384, line 1-14 -----	1-5, 7, 8
Y	page 386, line 31 -page 389, line 10 page 384, line 1-14 -----	1, 5, 8
X	WO 95 14683 A (DU PONT MERCK PHARMA) 1 June 1995 (1995-06-01) cited in the application page 7, line 3-33 page 273, line 1-5 -----	1, 5, 8
Y	-----	1, 5, 8
A	-----	3, 4, 7
	-----	-----

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

3 August 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

1

INTERNATIONAL SEARCH REPORT

Inte	lational Application No
PCT/US 00/06451	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEFKOVITS, JEFFREY ET AL: "Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model" J. AM. COLL. CARDIOL. (1996), 28(7), 1858-1865, XP000933719 page 1859; figure 1 page 1861, left-hand column page 1862, right-hand column -page 1863, left-hand column page 1864, left-hand column, paragraph 2	1,2,4,8
X	EP 0 735 050 A (HAMILTON CIVIC HOSPITALS RES) 2 October 1996 (1996-10-02) page 4, line 46-53; claims 1,3-5 page 5, line 15-21; claims 9,10 page 6, line 14-23; claims 15,17 page 8, line 34,35; claims 25,28,30 page 9, line 55-57 page 15, line 38-42	1,2,4, 6-8
X	EP 0 832 879 A (SQUIBB BRISTOL MYERS CO) 1 April 1998 (1998-04-01) page 12, line 56 -page 13, line 20	1,2,4,8
X	WO 96 40744 A (COR THERAPEUTICS INC) 19 December 1996 (1996-12-19) page 37, line 9-29 page 36, line 13-20 page 1, line 10-12	1,3,4,7, 8
X	WO 94 12204 A (MERCK & CO INC) 9 June 1994 (1994-06-09) page 30, line 22-26; claims 9,13-15,18,19	1,4,8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-8 relate to methods and uses defined by reference to compounds having desirable characteristics or properties, namely inhibition of Factor Xa and antagonism of GPIIb/IIIa. The claims cover all methods and uses involving compounds having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). Compounds are not sufficiently defined by their mechanism of action and/or their pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Furthermore, the claims relate to an extremely large number of possible compounds by means of the terms "low molecular weight heparin" and "subtherapeutic dose". Due thereto, a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search over the complete scope of the claims impossible.

Finally, support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods and uses involving compounds specifically defined in the claims and in the examples, with due regard to the description (especially specific compounds defined on page 4, line 28 - page 17, line 18) and to the general idea underlying the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int.	Joint Application No
PCT/US 00/06451	

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
DE 19816983	A	21-10-1999	AU WO	4030399 A 9954313 A	08-11-1999 28-10-1999
WO 9938827	A	05-08-1999	AU	2350699 A	16-08-1999
WO 9945913	A	16-09-1999		NONE	
WO 9828269	A	02-07-1998	AU CN EP HR LT NO PL SI US	5602098 A 1246847 A 0946508 A 970698 A 99076 A 992633 A 334250 A 20017 A 6020357 A	17-07-1998 08-03-2000 06-10-1999 31-10-1998 25-02-2000 20-08-1999 14-02-2000 29-02-2000 01-02-2000
WO 9514683	A	01-06-1995	AU AU BR CA CZ EP EP FI HR HU JP NO NZ PL SK US ZA	695853 B 1098095 A 9408137 A 2174838 A 9601419 A 0730590 A 0970950 A 962184 A 940952 A 74690 A 9505590 T 962096 A 276633 A 314591 A 66696 A 5849736 A 9409337 A	27-08-1998 13-06-1995 12-08-1997 01-06-1995 13-11-1996 11-09-1996 12-01-2000 23-05-1996 30-04-1997 28-01-1997 03-06-1997 23-05-1996 27-04-1998 16-09-1996 06-11-1996 15-12-1998 24-05-1996
EP 0735050	A	02-10-1996	US AU CA WO CN GB JP NO US US	5744457 A 5140096 A 2217054 A 9629973 A 1186502 A 2299998 A, B 11506420 T 974500 A 5763427 A 6001820 A	28-04-1998 16-10-1996 03-10-1996 03-10-1996 01-07-1998 23-10-1996 08-06-1999 28-11-1997 09-06-1998 14-12-1999
EP 0832879	A	01-04-1998	CA JP US AU	2185950 A 10114741 A 5610308 A 6582696 A	20-03-1998 06-05-1998 11-03-1997 26-03-1998
WO 9640744	A	19-12-1996	US AU AU CA EP JP	6069130 A 702360 B 6476196 A 2224180 A 0832102 A 11507337 T	30-05-2000 18-02-1999 30-12-1996 19-12-1996 01-04-1998 29-06-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l	ional Application No
PCT/US 00/06451	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9412204	A 09-06-1994	AU 5670494 A	22-06-1994